Literature DB >> 26424552

Down-regulation of PAR1 activity with a pHLIP-based allosteric antagonist induces cancer cell death.

Kelly E Burns1, Damien Thévenin2.   

Abstract

Even though abnormal expression of G protein-coupled receptors (GPCRs) and of their ligands is observed in many cancer cells of various origins, only a few anti-cancer compounds directly act on their signalling. One promising approach to modulate their activity consists of targeting the receptor cytoplasmic surfaces interacting with the associated G-proteins using peptides mimicking the intracellular loops of the receptor. Thus, to be fully effective, the peptide mimics must be selectively targeted to the tumour while sparing healthy tissues, translocated across the cell membrane and stay anchored to the cytoplasmic leaflet of the plasma membrane. In the present study, we introduce a novel way to selectively target and inhibit the activity of a GPCR in cancer cells under acidic conditions, such as those found in solid tumours. We find that the conjugation of a peptide fragment derived from the third intracellular loop (i3) of the protease-activated receptor 1 (PAR1) to a peptide that can selectively target tumours solely based on their acidity [pH(Low) Insertion Peptide (pHLIP)], produces a construct capable of effectively down-regulating PAR1 activity in a concentration- and pH-dependent manner and of inducing a potent cytotoxic effect in a panel of cancer cells that is proportional to the relative level of receptor expression at the cell surface. This strategy not only allows for a more selective targeting and specific intracellular delivery than current approaches, but also offers new possibilities for developing novel anti-cancer drugs targeting GPCRs.
© 2015 Authors; published by Portland Press Limited.

Entities:  

Keywords:  G protein-coupled receptor (GPCR); allosteric receptor modulation; cancer cytotoxicity; intracellular loops; peptide; targeted drug delivery; tumour acidity

Mesh:

Substances:

Year:  2015        PMID: 26424552      PMCID: PMC4663134          DOI: 10.1042/BJ20150876

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  32 in total

Review 1.  Protease-activated receptors: contribution to physiology and disease.

Authors:  Valeria S Ossovskaya; Nigel W Bunnett
Journal:  Physiol Rev       Date:  2004-04       Impact factor: 37.312

2.  Translocation of molecules into cells by pH-dependent insertion of a transmembrane helix.

Authors:  Yana K Reshetnyak; Oleg A Andreev; Ursula Lehnert; Donald M Engelman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-11       Impact factor: 11.205

3.  The pattern of Protease Activated Receptor 1 (PAR1) expression in endometrial carcinoma.

Authors:  Sorina Granovsky-Grisaru; Salah Zaidoun; Dan Grisaru; Yael Yekel; Diana Prus; Uziel Beller; Rachel Bar-Shavit
Journal:  Gynecol Oncol       Date:  2006-07-27       Impact factor: 5.482

4.  Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo.

Authors:  M L Nierodzik; F Kajumo; S Karpatkin
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

Review 5.  G protein-coupled receptors. II. Mechanism of agonist activation.

Authors:  U Gether; B K Kobilka
Journal:  J Biol Chem       Date:  1998-07-17       Impact factor: 5.157

Review 6.  Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.

Authors:  M M Goldenberg
Journal:  Clin Ther       Date:  1999-02       Impact factor: 3.393

7.  PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells.

Authors:  Adrienne Boire; Lidija Covic; Anika Agarwal; Suzanne Jacques; Sheida Sherifi; Athan Kuliopulos
Journal:  Cell       Date:  2005-02-11       Impact factor: 41.582

8.  PAR1-type thrombin receptor stimulates migration and matrix adhesion of human colon carcinoma cells by a PKCepsilon-dependent mechanism.

Authors:  Ilonka Heider; Beate Schulze; Elke Oswald; Peter Henklein; Johannes Scheele; Roland Kaufmann
Journal:  Oncol Res       Date:  2004       Impact factor: 5.574

9.  Thrombin receptor overexpression in malignant and physiological invasion processes.

Authors:  S Even-Ram; B Uziely; P Cohen; S Grisaru-Granovsky; M Maoz; Y Ginzburg; R Reich; I Vlodavsky; R Bar-Shavit
Journal:  Nat Med       Date:  1998-08       Impact factor: 53.440

10.  Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.

Authors:  Sorina Grisaru-Granovsky; Zaidoun Salah; Myriam Maoz; Diana Pruss; Uziel Beller; Rachel Bar-Shavit
Journal:  Int J Cancer       Date:  2005-01-20       Impact factor: 7.396

View more
  14 in total

1.  Therapeutic Efficacy of a Family of pHLIP-MMAF Conjugates in Cancer Cells and Mouse Models.

Authors:  Kelly E Burns; Harvey Hensley; Matthew K Robinson; Damien Thévenin
Journal:  Mol Pharm       Date:  2017-01-13       Impact factor: 4.939

2.  Comparison of lipid-dependent bilayer insertion of pHLIP and its P20G variant.

Authors:  Victor Vasquez-Montes; Janessa Gerhart; Kelly E King; Damien Thévenin; Alexey S Ladokhin
Journal:  Biochim Biophys Acta Biomembr       Date:  2017-11-11       Impact factor: 3.747

3.  Inhibiting Epidermal Growth Factor Receptor Dimerization and Signaling Through Targeted Delivery of a Juxtamembrane Domain Peptide Mimic.

Authors:  Janessa Gerhart; Anastasia F Thévenin; Elizabeth Bloch; Kelly E King; Damien Thévenin
Journal:  ACS Chem Biol       Date:  2018-08-31       Impact factor: 5.100

4.  Peptides of pHLIP family for targeted intracellular and extracellular delivery of cargo molecules to tumors.

Authors:  Linden C Wyatt; Anna Moshnikova; Troy Crawford; Donald M Engelman; Oleg A Andreev; Yana K Reshetnyak
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-05       Impact factor: 11.205

Review 5.  Targeting PAR1: Now What?

Authors:  Robert Flaumenhaft; Karen De Ceunynck
Journal:  Trends Pharmacol Sci       Date:  2017-05-27       Impact factor: 14.819

6.  pHLIP Peptide Interaction with a Membrane Monitored by SAXS.

Authors:  Theyencheri Narayanan; Dhammika Weerakkody; Alexander G Karabadzhak; Michael Anderson; Oleg A Andreev; Yana K Reshetnyak
Journal:  J Phys Chem B       Date:  2016-10-27       Impact factor: 2.991

7.  Selective Display of a Chemoattractant Agonist on Cancer Cells Activates the Formyl Peptide Receptor 1 on Immune Cells.

Authors:  Eden L Sikorski; Janessa Wehr; Noel J Ferraro; Sophia M Rizzo; Marcos M Pires; Damien Thévenin
Journal:  Chembiochem       Date:  2022-03-09       Impact factor: 3.461

Review 8.  Applications of pHLIP Technology for Cancer Imaging and Therapy.

Authors:  Linden C Wyatt; Jason S Lewis; Oleg A Andreev; Yana K Reshetnyak; Donald M Engelman
Journal:  Trends Biotechnol       Date:  2017-04-21       Impact factor: 19.536

9.  pH-Dependent Grafting of Cancer Cells with Antigenic Epitopes Promotes Selective Antibody-Mediated Cytotoxicity.

Authors:  Janessa Wehr; Eden L Sikorski; Elizabeth Bloch; Mary S Feigman; Noel J Ferraro; Trevor R Baybutt; Adam E Snook; Marcos M Pires; Damien Thévenin
Journal:  J Med Chem       Date:  2020-03-30       Impact factor: 7.446

10.  pH-Selective Cytotoxicity of pHLIP-Antimicrobial Peptide Conjugates.

Authors:  Kelly E Burns; Tanner P McCleerey; Damien Thévenin
Journal:  Sci Rep       Date:  2016-06-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.